Next Article in Journal
Steroids Conjugated to Carbon Nanoforms as Potential Inhibitors of Viral Proteases, Synthesis, DFT Calculations, and Molecular Docking
Previous Article in Journal
In Vitro Cytotoxicity of 7,3′,4′-Trihydroxyflavones in Lung Fibroblasts
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides †

by
Krzysztof Szafrański
1,*,
Jarosław Sławiński
1 and
Anna Kawiak
2
1
Department of Organic Chemistry, Medical University of Gdańsk, 80-416 Gdańsk, Poland
2
Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, 80-307 Gdańsk, Poland
*
Author to whom correspondence should be addressed.
Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.
Med. Sci. Forum 2022, 14(1), 51; https://doi.org/10.3390/ECMC2022-13280
Published: 1 November 2022
(This article belongs to the Proceedings of The 8th International Electronic Conference on Medicinal Chemistry)

Abstract

:
During our research of biological activity of different N-aryl-4-substututed-pyridine-3-sulfonamides, we have found that compounds bearing a N-(quinolin-8-yl) substituent possess a significant anti-tumor activity. Mechanisms of anticancer activity of N-(quinoline)sulfonamide derivatives were reported to be inhibitors of the NF-κB pathway. Nuclear factor NF-κB regulates expression of genes that control cell proliferation and cell survival; thus, it is considered a potential molecular target for the prevention and treatment of cancer. Based on this information, we decided to synthesize and evaluate a series of 4-amino-N-(quinolin-8-yl)pyridine-3-sulfonamides, which contain both a 8-amonoquinolin group and a pyridine-3-sulfonamide scaffold. Target compounds were obtained in a multistep reaction starting from 4-hydroxypyridine, and their structure was confirmed using the spectroscopic methods: IR, 1H NMR, and elemental analysis (C, H, N). Synthesized compounds were tested using a tetrazolium (MTT) cell viability assay towards their effect on growth of three human cancer cell lines (colon cancer HCT-116, breast cancer MCF-7 and cervical cancer HeLa) and on the noncancerous keratinocyte cell line HaCaT. Cell viability was measured after 72 h of incubation with the tested compound in five concentrations (1–100 μM). All compounds show very high activity compared to cisplatin against cancer cells lines (IC50 = 4–43 μM), and a selectivity relative to HaCaT cells.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ECMC2022-13280/s1.

Author Contributions

Conceptualization, K.S. and J.S.; methodology, K.S.; formal analysis, K.S.; investigation, K.S. and A.K.; data curation, K.S. and A.K.; writing—original draft preparation, K.S.; writing—review and editing, J.S.; visualization, K.S.; supervision, J.S.; project administration, K.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Szafrański, K.; Sławiński, J.; Kawiak, A. Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides. Med. Sci. Forum 2022, 14, 51. https://doi.org/10.3390/ECMC2022-13280

AMA Style

Szafrański K, Sławiński J, Kawiak A. Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides. Medical Sciences Forum. 2022; 14(1):51. https://doi.org/10.3390/ECMC2022-13280

Chicago/Turabian Style

Szafrański, Krzysztof, Jarosław Sławiński, and Anna Kawiak. 2022. "Anticancer Evaluation of 4-substituted-N-(quinolin-8-yl)pyridine-3-sulfonamides" Medical Sciences Forum 14, no. 1: 51. https://doi.org/10.3390/ECMC2022-13280

Article Metrics

Back to TopTop